TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06330064: A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Sponsor: Daiichi Sankyo · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 680 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06330064 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06330064 Rescue Dossier →